AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04021693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handheld Ultrasound Devices
Description: Interns in the handheld ultrasound device arm shall carry a personal handheld ultrasound device to be used for self-directed learning
Study NCT03853278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: colorectal cancer self-management
Description: The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
Study NCT03767790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iAPS
Description: The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
Study NCT03292172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
Study NCT03292172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
Study NCT02901678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrusion by 400 g
Description: using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
Study NCT02901678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrusion by 400 g
Description: using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
Study NCT02033564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh/Miller Laryngoscope
Study NCT01281332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menopod
Description: The mechanism of action of the device will not be revealed in advance.
Study NCT01281332 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive device
Study NCT00357279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denufosol tetrasodium (INS37217) Inhalation Solution
Description: Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
Study NCT00357279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - 0.9% w/v sodium chloride solution
Description: 4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
Study NCT02033564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Laryngoscope
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study NCT02018731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Metformin & L-Citrulline
Study NCT02018731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline and Metformin & L-Citrulline
Study NCT02601339 — intervention group
Intervention type: PROCEDURE
Intervention: ETV/CPC
Description: endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study NCT02152956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral inhibitor of JAK kinase
Study NCT02152956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose
Description: Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
Study NCT02369744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silodosin
Description: 8mg tablet, 1 tab PO daily for 2 weeks
Study NCT02369744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg Tab, 1 tab PO daily for 2 weeks
Study NCT03241147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single dose, 10 mg film coated tablet
Study NCT04521049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg
Description: Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR \<50 mL/min/1.73 m2
Study NCT03269708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education regarding telomere length
Description: Teaching concepts of cellular aging and telomere length
Study NCT00710073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sono-electro-magnetic therapy (Sonodyn Medico Star)
Description: twice a day for 10 minutes during 6 or 12 weeks
Study NCT05307029 — intervention group
Intervention type: PROCEDURE
Intervention: rehabilitation with fixed full-arch prosthesis
Study NCT02177201 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group 1
Description: Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
Study NCT02177201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
Study NCT00894556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan
Description: Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
Study NCT01388985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Diploid Cell Vaccine (HDCV) rabies vaccine
Description: Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
Study NCT01388985 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Diploid Cell Vaccine (HDCV) rabies vaccine
Description: Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
Study NCT02202083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cook Balloon
Description: There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6.
Study NCT01519167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.1 - 1.0 mcg/kg/hr IV
Study NCT01519167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0.025 - 2 mg/kg IV
Study NCT01519167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.5 - 3 mcg/kg IV
Study NCT01643096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Zataria multiflora Boiss
Description: Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
Study NCT00894556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo to Rizatriptan
Study NCT00894556 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Sumatriptan
Description: single dose of generic sumatriptan 100 mg at onset of migraine attack
Study NCT02860312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradialytic exercise on stationary bicycles
Description: Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
Study NCT01643096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sumac
Description: Thermic effect of food of Sumac and comparison between hot and cold temperament people
Study NCT02860312 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-exercising group
Description: Patients are having their usual physical activity
Study NCT04119466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilizing training
Description: The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
Study NCT03366519 — intervention group
Intervention type: PROCEDURE
Intervention: clinical echography (CE)
Description: clinical echography (CE) is performed in the first 24 hours following the diagnosis of PE, in emergency unit
Study NCT03787498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: Tablets
Study NCT02200640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Micardis®, once daily
Study NCT02200640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Micardis®, once daily
Study NCT02200640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of COZAAR®, once daily
Study NCT02200640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose of COZAAR®, once daily
Study NCT02200640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02200640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00645957 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: penrose drain
Description: incision and drainage of the infection with placement of a penrose drain
Study NCT04371393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
Study NCT04371393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
Study NCT00571168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emend
Description: 125 mg/d on day 1; 80 mg/d on day 2-4
Study NCT00645957 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: red rubber drain
Description: incision and drainage of infection and placement of a red rubber drain
Study NCT00571168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules on day 1-4
Study NCT03753113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Herbal Solution
Description: Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
Study NCT03753113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Minoxidil 5%
Description: Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
Study NCT03753113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minoxidil 5%
Description: Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
Study NCT02252939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X-Ray
Description: X-ray as part of standard care
Study NCT04017481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
Study NCT01315561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture, injection
Description: MSAT and intramuscular injections of diclofenac(NSAID)
Study NCT01315561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture, injection
Description: MSAT and intramuscular injections of diclofenac(NSAID)
Study NCT03353519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care model
Description: Specifically, the intervention will comprise the following components:~1. Structured review of patient needs;~2. A self-management programme (MLAS) for stroke survivors and their carers;~3. A direct point of contact for stroke survivors and carers at the GP surgery;~4. Optimised communication between General Practice staff and specialist services;~5. Service mapping for stroke related needs;~6. Training for General Practice staff.
Study NCT03666364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sperm preparation for ICSI
Description: A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women
Study NCT03859362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem Injection
Description: 1 g of ertapenem q24h, 30 min infusion
Study NCT01710813 — intervention group
Intervention type: BIOLOGICAL
Intervention: alglucosidase alfa
Description: Alglucosidase alfa IV infusion of 20 mg/kg; qow
Study NCT05388292 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emergency triage decision support system
Description: Evaluating the impact of the developed Emergency Triage Decision Support System on triage management
Study NCT03304249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iAmHealthy Healthy Lifestyles Program
Description: iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
Study NCT04017481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG guided Neurofeedback (NFB)
Description: The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
Study NCT02522702 — intervention group
Intervention type: OTHER
Intervention: Photography of polyps, resection of polyps
Description: Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
Study NCT00575627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon alpha2a plus Ribavirin
Description: Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
Study NCT03304249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter
Description: Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
Study NCT04580992 — intervention group
Intervention type: DRUG
Intervention: Ajmaline
Description: Ajmaline administration
Study NCT03008356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine 1000 mg twice daily
Description: Oral L-carnitine to be taken twice daily for 8 weeks
Study NCT01039103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-liposomal prednisolone sodium phosphate
Description: PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
Study NCT03008356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly health coaching calls
Description: Weekly health coaching calls lasting 10-15 minutes
Study NCT01039103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
Study NCT02538354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Description: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
Study NCT03008356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT01258504 — intervention group
Intervention type: DRUG
Intervention: St. Johns Wort
Description: * Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20
Study NCT00764595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
Study NCT04096274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership for Organization Change and Implementation (LOCI)
Description: LOCI is a multicomponent implementation strategy that engages organizational executives and first-level leaders (i.e., those who administratively supervise clinicians) to build an organizational climate to support the implementation of a focal evidence-based practice (EBP) with fidelity. In this study, the focal EBP is the OQ-A system. LOCI includes two overarching components: (1) monthly organizational strategy meetings between executives and LOCI consultants/trainers to develop and embed policies, procedures, and practices that support implementation of a focal EBP, and (2) training and coaching for first-level leaders, to develop their skills in leading implementation. The aim of these components is to develop an organizational implementation climate in which clinicians' perceive that use of the OQ-A with high fidelity is expected, supported, and rewarded.
Study NCT04096274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Technical Assistance Only
Description: All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback.
Study NCT04435717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1
Description: Tocilizumab 20 MG/ML Intravenous (one dose)
Study NCT04435717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)
Description: Tocilizumab 20 MG/ML Intravenous ( two doses)
Study NCT01696513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction